Analysis Episurf Medical AB (0QUT)
6/1/2024
Analysis of Episurf Medical AB (0QUT)
Episurf Medical AB is a company that specializes in developing personalized implants and surgical instruments for patients with cartilage damage in joints. The company aims to provide innovative solutions for individualized treatment, focusing on improving patient outcomes and quality of life.Looking at the recent data provided, we can see that the stock price of Episurf Medical AB (symbol: 0QUT) has been fluctuating within a certain range. The Relative Strength Index (RSI) values indicate that the stock has been in the oversold territory, suggesting a possible buying opportunity. However, it's important to note that the Moving Average Convergence Divergence (MACD) indicators are not available, which limits our ability to assess the momentum of the stock.
In terms of moving averages, the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) values provide different perspectives on the stock's performance. The EMA and WMA values are generally higher than the SMA, indicating a potential bullish trend. However, further analysis is needed to confirm this trend.
Overall, Episurf Medical AB appears to be an interesting company with a focus on innovative medical solutions. Investors interested in this stock should consider conducting a more in-depth analysis, considering additional factors such as market trends, competition, and financial performance.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show a pattern of common stock repurchase and issuance, as well as long-term debt issuance and payments.
5. Investing activities include the sale and purchase of investments, capital expenditures, and other investing activities.
6. The end cash position has also been fluctuating, reaching its highest value in 2020.
7. Stock-based compensation has been a significant factor in the company's financial activities.
8. The company has been paying dividends to common shareholders, with varying amounts each year.
9. Overall, the company's financial performance and cash flow management have shown some variability but also some consistency in key areas over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows growth compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This indicates an increase from the EPS of $1.35 in the same quarter last year.
3. For the current year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth from the EPS of $5.67 for the previous year.
4. Looking ahead to the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a potential increase from the EPS of $6.10 in the current year.
Overall, the analysts' estimates indicate a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, showing a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate to strong growth expected in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slight slowdown compared to the past 5 years but still showing healthy growth rates for the upcoming periods.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it can be observed that the analysts have a relatively wide range of expectations for the future price of the security, with the low end at $164 and the high end at $250. The median and average forecasts are $200 and $202.26, respectively. The current price of the security is $191.57. It appears that the analysts are generally optimistic about the future price of the security, with the average forecast being higher than the current price.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a relatively low short ratio and a significant percentage of shares held by institutions. The stock price summary shows the stock's performance over the past year, with a beta of 1.264 and a 52-week change of 6.853%.
Valuation metrics reveal the company's price-to-earnings ratios, enterprise value, and market capitalization. The company's stock is trading at a premium based on these metrics.
Lastly, dividends and splits information shows the company's dividend history, payout ratio, and dividend yield. The company has a regular dividend payout and has undergone a stock split in the past.
Overall, the data provides a comprehensive overview of the company's financial health, stock performance, valuation, and dividend policy.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe that the company has experienced a steady increase in revenue from 2020 to 2022, with a slight decrease in 2023. This trend indicates a generally positive growth trajectory in terms of sales over the past few years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
